Research progress of anti-acute marrow leukemia drugs by targeting FLT3 / 药学学报
Hui-ya JIA; Bo YANG; Xiao-meng ZHANG; Jian-hong GONG; Ya WU; Yan-le ZHI.
Acta Pharmaceutica Sinica
; (12): 605-615, 2023.
Artículo
en Zh
| WPRIM | ID: wpr-965615
Acute myeloid leukemia (AML) is a genetic heterogeneous disease in which primordial and juvenile myeloid cells proliferate or accumulate abnormally in bone marrow, peripheral blood and other tissues, resulting in damage to normal hematopoietic function. Studies have shown that about 30% of AML patients have FMS-like tyrosine kinase 3 (FLT3), FLT3 abnormal regulation is closely related to the occurrence and development of AML. At present, FLT3 has become an important target for developing small molecular targeted drugs. Currently, a variety of FLT3 inhibitors and FLT3 degraders have been developed targeting FLT3, and some compounds have exhibited good anti-AML activity. This article summarizes and sorts out the current mainstream drugs for AML therapeutic targeting FLT3, in order to provide a reference for the development and design of AML drugs.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados